NTBL (Notable Labs Inc.) Gross Profitability

Corporate emblem and logo of Notable Labs Inc. (NTBL)

The gross margin distribution of Notable Labs, Ltd. (NTBL) demonstrates the biotech sector's resilience to crises, where 0.00 reflects the latest metric value. Business efficiency is based on the medical community's recognition of its algorithms and access to biological samples. Current growth relies on the expansion of IT models and B2B contracts with hospitals, which determines the company's market value through the lens of its profitability.

NTBL: Notable Labs Inc. Gross Margin 02/21/2024 - 11/02/2024

Analytical breakdowns and data insights for company Notable Labs, Ltd. (NTBL)

- market value and analyst target forecast:
- business market valuation indicators:
Fundamental valuation:Notable Labs, Ltd.
Manufactured products of Notable Labs Corp

For Notable Labs, Ltd. (NTBL), which develops precision oncology therapy through functional live-cell diagnostics, this indicator reflects the monetization efficiency of personalized treatment. The metric is calculated as the difference between total revenue and direct test production costs, determining the portion of capital available to cover operating expenses. By analyzing the gross profit margin, an investor identifies the scalability of the business model and the risk of erosion of the asset's intrinsic value.

Direct competitors

Gross Profit Margin BeiGene Ltd. (ONC)|Return on Gross Profit HALO|Gross Profitability RVMD|Return on Gross Profit AAPG (Ascentage)|Return on Gross Profit cgoncology.com CGON|UroGen Pharma - Return on Gross Profit|Gross Profit Rate BCAX|PSNL - Gross Profitability|Return on Sales by Gross Profit Erasca Oncology ERAS|delcath.com (DCTH) - Gross Profitability|Y-mAbs Therapeutics - Gross Profit Rate|AURA (Aura Biosciences Inc) - Gross Margin|Gross Profit Margin candeltx.com CADL|Gross Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Gross Profit Rate|Gross Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Gross Profitability|TuHURA Biosciences Inc. - Gross Margin|TARA - Gross Margin|FATE (Fate Therapeutics) - Return on Gross Profit|Return on Gross Profit Aadi Bioscience, Inc.|Return on Gross Profit TCRX|Gross Profitability CSBR|Gross Margin XBIT|Return on Sales by Gross Profit CEL-SCI Corp.|Gross Profitability ostherapies.com OSTX|RADX: Gross Return on Sales|ARTV: Return on Gross Profit|ANL (Adlai Nortye) - Gross Return on Sales|Veru (VERU) - Gross Profitability|Return on Gross Profit Tempest Therapeutics Inc|Gross Profitability Xilio Therapeutics|Gross Return on Sales RENB (Renovaro Inc.)|Gross Profitability Mural Oncology PLC (MURA)|Gross Margin Kairos Pharma (KAPA)|Gross Profitability onkuretherapeutics.com OKUR|GDTC: Gross Return on Sales|CRIS: Return on Gross Profit|apollomicsinc.com (APLM) - Return on Gross Profit|THAR: Gross Margin|Return on Gross Profit Advanced Biomed Inc.|Return on Gross Profit GNPX|Gross Return on Sales CLDI (Calidi Biotherapeutics)|Gross Margin SBFM|Xenetic Biosciences, Inc. - Gross Return on Sales|Gross Profitability Salarius Pharmaceuticals SLRX|Gross Margin purple-biotech.com PPBT|AONC - Gross Profitability|BGNE: Gross Profitability|CKPT: Gross Margin|Elevation Oncology - Gross Profit Rate|ICAD (iCAD) - Gross Margin|IKNA: Gross Profit Rate|Return on Gross Profit VIRX (Viracta Therapeutics Inc.)|MOR - Gross Profit Margin|Gross Profitability NAYA Biosciences NAYA|AAPGV - Return on Gross Profit